{"id":4013,"date":"2025-06-27T12:29:23","date_gmt":"2025-06-27T09:29:23","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4013"},"modified":"2025-06-27T12:29:24","modified_gmt":"2025-06-27T09:29:24","slug":"entrada-therapeutics-begins-clinical-trials-in-europe-for-exon-44-and-exon-45-skipping-therapies","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/entrada-therapeutics-begins-clinical-trials-in-europe-for-exon-44-and-exon-45-skipping-therapies\/","title":{"rendered":"Entrada Therapeutics inicia ensayos cl\u00ednicos en Europa para terapias de omisi\u00f3n del ex\u00f3n 44 y 45"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Entrada Therapeutics ha lanzado oficialmente ensayos cl\u00ednicos en Europa para sus innovadoras terapias de omisi\u00f3n de exones dirigidas al ex\u00f3n 44 y al ex\u00f3n 45, lo que marca un hito significativo en el tratamiento de la distrofia muscular de Duchenne (DMD).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Estas terapias en investigaci\u00f3n est\u00e1n dise\u00f1adas para abordar mutaciones gen\u00e9ticas espec\u00edficas en pacientes con DMD, con el objetivo de restaurar la producci\u00f3n de distrofina y mejorar los resultados cl\u00ednicos. El inicio de estos ensayos pone de relieve el compromiso de Entrada con el avance de la medicina gen\u00e9tica de precisi\u00f3n y la expansi\u00f3n del acceso global a nuevos tratamientos para enfermedades neuromusculares raras. \u2013 Leer m\u00e1s: <a href=\"https:\/\/dmdwarrior.com\/es\/what-is-exon-skipping-and-how-does-it-work\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u00bfQu\u00e9 es la omisi\u00f3n de ex\u00f3n y c\u00f3mo funciona?<\/a> \u2013<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Tabla de contenido<\/h2><nav><ul><li><a href=\"#entrada-exon-44-skipping-nct-07037862\">Entrada Salto del ex\u00f3n 44 \u2013 NCT07037862 \u2013<\/a><\/li><li><a href=\"#entrada-exon-45-skipping-nct-07038824\">Entrada Salto del ex\u00f3n 45 \u2013 NCT07038824 \u2013<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"entrada-exon-44-skipping-nct-07037862\">Entrada Salto del ex\u00f3n 44 \u2013 NCT07037862 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Este es un estudio del medicamento en investigaci\u00f3n ENTR-601-44 en participantes que padecen distrofia muscular de Duchenne (DMD), una enfermedad gen\u00e9tica poco com\u00fan.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Inicio del estudio (estimado)<\/strong>: 2025-06-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Finalizaci\u00f3n primaria (estimada)<\/strong>: 2029-03-28<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Finalizaci\u00f3n del estudio (estimada)<\/strong>: 2029-03-28<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00famero de participantes (estimado)<\/strong>: 24<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ubicaciones<\/strong>:B\u00e9lgica, Italia, Espa\u00f1a, Reino Unido.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Edades elegibles para estudiar<\/strong>: 4 a\u00f1os a 20 a\u00f1os (ni\u00f1o, adulto)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Criterios principales de inclusi\u00f3n y exclusi\u00f3n. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07037862\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07037862<\/a> \u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"entrada-exon-45-skipping-nct-07038824\">Entrada Salto del ex\u00f3n 45 \u2013 NCT07038824 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Este es un estudio del medicamento en investigaci\u00f3n ENTR-601-45 en participantes que padecen distrofia muscular de Duchenne (DMD), una enfermedad gen\u00e9tica poco com\u00fan.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Inicio del estudio (estimado)<\/strong>: 2025-09-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Finalizaci\u00f3n primaria (estimada)<\/strong>: 2029-03-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Finalizaci\u00f3n del estudio (estimada)<\/strong>: 2029-03-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00famero de participantes (estimado)<\/strong>: 24<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ubicaciones<\/strong>:B\u00e9lgica, Italia, Pa\u00edses Bajos, Espa\u00f1a, Reino Unido.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Edades elegibles para estudiar<\/strong>: 4 a\u00f1os a 20 a\u00f1os (ni\u00f1o, adulto)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Criterios principales de inclusi\u00f3n y exclusi\u00f3n. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07038824\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07038824<\/a> \u2013<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/dmdwarrior.com\/es\/tag\/entrada-therapeutics\/\">Lea m\u00e1s sobre Entrada Therapeutics<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Entrada Therapeutics has officially launched clinical trials in Europe for its innovative exon skipping therapies targeting Exon 44 and Exon 45\u2014marking a significant milestone in the treatment of Duchenne muscular dystrophy (DMD). These investigational therapies are designed to address specific genetic mutations in DMD patients, with the goal of restoring dystrophin production and improving clinical [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4021,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[242,233,234,84,246,319,178],"class_list":["post-4013","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trials","tag-entrada","tag-entrada-therapeutics","tag-europe","tag-exon-44-skipping-therapies","tag-exon-45-skipping-therapy","tag-exon-skipping-therapies"],"subtitle":"Entrada Therapeutics ha dado un gran paso adelante en la lucha contra la distrofia muscular de Duchenne (DMD) al iniciar ensayos cl\u00ednicos en Europa para sus terapias de omisi\u00f3n de exones dirigidas a las mutaciones del ex\u00f3n 44 y el ex\u00f3n 45.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=4013"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4013\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/4021"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=4013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=4013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=4013"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}